Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Angiogenesis in myeloproliferative neoplasms, new markers and future directions

Angiogenesis in myeloproliferative neoplasms, new markers and future directions Tumor angiogenesis has been identified to play a critical role in tumor growth and tumor progression, and is regulated by a balance of angiogenic and antiangiogenic cytokines. This has been documented for solid tumors, and there is emerging evidence suggesting that tumor progression of hematological malignancies also depends on the induction of new blood vessel formation. Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative neoplasm patients suggest an increase of the microvessel density and vascular endothelial growth factor (VEGF) expression, and there is a relation to the JAK2-V617F status. The most important proangiogenic agent is VEGF, activating VEGF receptors 1 and 2. Inhibition of VEGF signaling by monoclonal antibodies or small molecules (kinase inhibitors) has already been successfully established for the treatment of different cancer entities, and multiple new drugs are being tested in clinical trials. Most patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) that was not associated with a JAK2 or MPL alteration carried a somatic mutation in calreticulin (CALR). Thus, CALR mutations should be included in the next classification system for ET/PMF. This review summarizes recent advances in the basic understanding of the role of angiogenesis in myeloproliferative neoplasms and the translation of such basic findings into clinical studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Angiogenesis in myeloproliferative neoplasms, new markers and future directions

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/angiogenesis-in-myeloproliferative-neoplasms-new-markers-and-future-sud6Om8yS5
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0142-z
Publisher site
See Article on Publisher Site

Abstract

Tumor angiogenesis has been identified to play a critical role in tumor growth and tumor progression, and is regulated by a balance of angiogenic and antiangiogenic cytokines. This has been documented for solid tumors, and there is emerging evidence suggesting that tumor progression of hematological malignancies also depends on the induction of new blood vessel formation. Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative neoplasm patients suggest an increase of the microvessel density and vascular endothelial growth factor (VEGF) expression, and there is a relation to the JAK2-V617F status. The most important proangiogenic agent is VEGF, activating VEGF receptors 1 and 2. Inhibition of VEGF signaling by monoclonal antibodies or small molecules (kinase inhibitors) has already been successfully established for the treatment of different cancer entities, and multiple new drugs are being tested in clinical trials. Most patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) that was not associated with a JAK2 or MPL alteration carried a somatic mutation in calreticulin (CALR). Thus, CALR mutations should be included in the next classification system for ET/PMF. This review summarizes recent advances in the basic understanding of the role of angiogenesis in myeloproliferative neoplasms and the translation of such basic findings into clinical studies.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 22, 2014

References

  • Angiogenesis in cancer, vascular, rheumatoid and other disease
    Folkman, J
  • Tumor angiogenesis: therapeutic implications
    Folkman, J
  • Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
    Shweiki, D; Itin, A; Soffer, D; Keshet, E
  • Angiogenesis and antiangiogenic therapy in hematologic malignancies
    Dong, X; Han, ZC; Yang, R
  • Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    Frater, JL; Kay, NE; Goolsby, CL; Crawford, SE; Dewald, GW; Peterson, LC
  • Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
    Gille, H; Kowalski, J; Li, B
  • The biology of VEGF and its receptors
    Ferrara, N; Gerber, HP; LeCouter, J
  • A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R; Passamonti, F; Buser, AS
  • Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
    Kralovics, R; Teo, SS; Li, S; Theocharides, A
  • Somatic mutations of calreticulin in myeloproliferative neoplasms
    Klampfl, T; Gisslinger, H; Harutyunyan, AS
  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    Nangalia, J; Massie, CE; Baxter, EJ
  • Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status
    Medinger, M; Skoda, R; Gratwohl, A
  • Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
    Lundberg, LG; Lerner, R; Sundelin, P; Rogers, R; Folkman, J; Palmblad, J
  • Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD)
    Wrobel, T; Mazur, G; Surowiak, P; Wolowiec, D; Jelen, M; Kuliczkowsky, K
  • Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations
    Boveri, E; Passamonti, F; Rumi, E
  • VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders
    Gianelli, U; Vener, C; Raviele, PR
  • Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies
    Medinger, M; Fischer, N; Tzankov, A
  • Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells
    Gougos, A; Letarte, M
  • Endoglin (CD105): a marker of tumor vasculature and potential target for therapy
    Dallas, NA; Samuel, S; Xia, L
  • Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies
    Fonsatti, E; Del Vecchio, L; Altomonte, M
  • Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells
    Warrington, K; Hillarby, MC; Li, C; Letarte, M; Kumar, S
  • Clinical trials with anti-angiogenic agents in hematological malignancies
    Medinger, M; Mross, K
  • Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, B; Eisen, T; Stadler, WM
  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Motzer, RJ; Hutson, TE; Tomczak, P
  • Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours
    Mross, K; Drevs, J; Müller, M
  • PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    Giles, FJ; List, AF; Carroll, M
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H; Fehrenbacher, L; Novotny, W
  • Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer
    Sandler, A; Gray, R; Perry, MC
  • Single agent bevacizumab for myelofibrosis: results of the myeloproliferative disorders research consortium trial
    Mesa, RA; Silver, RT; Verstovsek, S
  • Antitumor activity of thalidomide in refractory multiple myeloma
    Singhal, S; Mehta, J; Desikan, R
  • Thalidomide-effect on T cell subsets as a possible mechanism of action
    Moncada, B; Baranda, ML; Gonzalez-Amaro, R; Urbina, R; Loredo, CE
  • Thalidomide is an inhibitor of angiogenesis
    D’Amato, RJ; Loughnan, MS; Flynn, E; Folkman, J
  • Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
    Gupta, D; Treon, SP; Shima, Y
  • Properties of thalidomide and its analogues: implications for anticancer therapy
    Teo, SK
  • Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects
    Dredge, K; Marriott, JB; Macdonald, CD
  • Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma
    De Luisi, AF; Coluccia, AM
  • Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Thomas, DA; Giles, FJ; Albitar, M
  • Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Tefferi, A; Cortes, J; Verstovsek, S
  • Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
    Quintás-Cardama, A; Kantarjian, HM; Manshouri, T
  • Long-term outcome of pomalidomide therapy in myelofibrosis
    Begna, KH; Pardanani, A; Mesa, R
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    Verstovsek, S; Mesa, RA; Gotlib, J
  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    Harrison, C; Kiladjian, JJ; Al-Ali, HK
  • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    Cervantes, F; Vannucchi, AM; Kiladjian, JJ